SAN FRANCISCO – Six abstracts exploring key issues in the treatment of gastrointestinal cancers will be presented at the 2017 Gastrointestinal Cancers Symposium, taking place January 19-21 at the Moscone West Building in San Francisco. These notable abstracts feature insights into the treatment and management of biliary, liver, and colorectal cancers; the effect of low-dose aspirin use in patients with colorectal cancer; and the role of omega-3 fatty acid and fish intake after a colon cancer diagnosis.

Experts in gastrointestinal cancers are available on-site to comment on the studies below.

**Abstract 225:**

*Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.*

Oral Abstract Session B  
Friday, January 20, 2017: 2:00 PM – 2:10 PMPST  
The Moscone West Building, Level 2, Ballroom  
Julien Edeline, MD  
Oncology Medical Eugene Marquis  
Comprehensive Cancer Center  
Rennes, France

**Abstract 344:**

*Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.*
Abstract 519:  
*Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.*

Poster Session C  
Saturday, January 21, 2017: 7:00 AM – 7:55 AM PST  
Saturday, January 21, 2017: 12:30 PM – 2:00 PM PST  
The Moscone West Building, Level 1, West Hall  
Michael Overman, MD  
The University of Texas  
MD Anderson Cancer Center  
Houston, Texas

Abstract 520:  
*Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).*

Poster Session C  
Saturday, January 21, 2017: 7:00 AM – 7:55 AM PST  
Saturday, January 21, 2017: 12:30 PM – 2:00 PM PST  
The Moscone West Building, Level 1, West Hall  
Scott Kopetz, MD, PhD, FACP  
The University of Texas  
MD Anderson Cancer Center  
Houston, Texas

Abstract 527:  
*Comparing mortality of colorectal cancer and gastrointestinal bleeding among patients with long-term use of low dose aspirin: A population-based study of 689,209 patients.*
Abstract 585:

*Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance).*
research and educational programs. On a monthly basis, the AGA Institute publishes two highly respected journals, *Gastroenterology* and *Clinical Gastroenterology and Hepatology*, and has recently launched a third journal, *Cellular and Molecular Gastroenterology and Hepatology*. The organization's annual meeting is **Digestive Disease Week®**, which is held each May and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The **AGA Research Foundation** provides digestive disease research grants on behalf of the AGA Institute.

For more information and to join, visit gastro.org/membership.

**About the American Society for Radiation Oncology:**
The American Society for Radiation Oncology (ASTRO) is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologist, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, *International Journal of Radiation Oncology, Biology, Physics*, *Practical Radiation Oncology*, and *Advances in Radiation Oncology*, developed and maintains an extensive patient website and created the **Radiation Oncology Institute**, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. Learn more about ASTRO.

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.

**About the Society of Surgical Oncology:**
The Society of Surgical Oncology (SSO) is the premier organization for surgeons and health care providers dedicated to advancing and promoting the science and treatment of cancer. The Society’s focus on all solid-tumor disease sites is reflected in its Annual Cancer Symposium,
monthly scientific journal (Annals of Surgical Oncology), educational initiatives, and committee structure. The Society’s mission is to improve multidisciplinary patient care by advancing the science, education, and practice of cancer surgery worldwide. SSO’s 2016-2017 President is Daniel G. Coit, MD, Professor of Surgery with Weill Cornell Medical College and surgical oncologist with Memorial Sloan Kettering Cancer Center. For more information, visit surgonc.org or SSO2016.org.